Morteza Salehjahromi

The University of Texas MD Anderson Cancer Center

MedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study”.

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

The Lancet Digital Health(2023)10.1016/s2589-7500(23)00082-1

N/A

0.708DataRank · unranked

111 citations

Lingzhi Hong, Muhammad Aminu, Natalie I. Vokes, Pingjun Chen, Morteza Salehjahromi +44 more

Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

Nature Communications(2024)10.1038/s41467-024-47512-0

N/A

0.672DataRank · unranked

87 citations

Muhammad Aminu, Tatiana V. Karpinets, Pingjun Chen, Maliazurina B. Saad, Morteza Salehjahromi +32 more

Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101463

N/A

0.546DataRank · unranked

37 citations

Tatiana V. Karpinets, Sheeba J. Sujit, Mohamed Qayati, Pingjun Chen, Muhammad Aminu +32 more

Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19

Cancers(2022)10.3390/cancers15010275

N/A

0DataRank · unranked

11 citations

Divya Yadav, Lingzhi Hong, Elliana Young, Paul Edelkamp, Maliazurina B. Saad +23 more

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-013074

N/A

0DataRank · unranked

4 citations

Eman Showkatian, Vivek Verma, Qasem Al-Tashi, Muhammad Aminu, Xinyan Xu +17 more

Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients

Cancers(2025)10.3390/cancers17213406

N/A

0DataRank · unranked

1 citations

Hui Li, Eman Showkatian, Maliazurina B. Saad, Mohamed Qayati, Sohair Ismail +25 more